Advanced search
Publication Cover
Cancer Investigation Volume 39, 2021 - Issue 3
Submit an article Journal homepage
167
Views
2
CrossRef citations to date
0
Altmetric
Articles

Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer

Takuya Yamashitaa Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Masaki Shiotaa Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3306-4858
ORCID Icon,
Asako Machidoria Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Satoshi Kobayashia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Takashi Matsumotoa Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Keisuke Monjia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Eiji Kashiwagia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Ario Takeuchia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Ryosuke Takahashia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Junichi Inokuchia Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Ken-ichiro Shigab Department of Urology, Harasanshin Hospital, Fukuoka, Japan
,
Akira Yokomizob Department of Urology, Harasanshin Hospital, Fukuoka, Japan
&
Masatoshi Etoa Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
 show all
Pages 251-256 | Received 29 Jul 2020, Accepted 30 Dec 2020, Published online: 14 Jan 2021

References

  • Shiota M, Yokomizo A, Eto M. Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy. Front Oncol. 2015;5:304. doi:10.3389/fonc.2015.00304.
  • Shiota M, Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23(5):360–369. doi:10.1111/iju.13091.
  • Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231. doi:10.1111/iju.13512.
  • Fujimoto N. Novel agents for castration-resistant prostate cancer: Early experience and beyond. Int J Urol. 2016;23(2):114–121. doi:10.1111/iju.12907.
  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. doi:10.1056/NEJMoa040720.
  • Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi:10.1056/NEJMoa041318.
  • Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5(2):119–126. doi:10.1016/j.jgo.2013.12.001.
  • Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, et al. Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Cancer Chemother Pharmacol. 2019;84(3):561–566. doi:10.1007/s00280-019-03874-7.
  • Shiota M, Yokomizo A, Adachi T, Koga H, Yamaguchi A, Imada K, et al. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer. Jpn J Clin Oncol. 2014;44(9):860–867. doi:10.1093/jjco/hyu081.
  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al.; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–1159. doi:10.1200/JCO.2007.12.4487.
  • Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, et al. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. Support Care Cancer. 2014;22(12):3219–3226. doi:10.1007/s00520-014-2328-7.
  • Kita Y, Shimizu Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients. Int J Clin Oncol. 2013;18(4):718–723. doi:10.1007/s10147-012-0443-3.
  • Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al.; PROSTY study group. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117–124. doi:10.1016/S1470-2045(12)70537-5.
  • Kim HS, Lee JY, Lee SJ, Lim HY, Sung HH, Jeon HG, et al. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. BMC Urol. 2017;17(1):63. doi:10.1186/s12894-017-0253-z.
  • Malhotra A, Welch D, Rosenbaum P, Poiesz BJ. Efficacy and toxicity of every 2 weeks docetaxel regimen in comparison with weekly or every 3 weeks in metastatic prostate cancer: a retrospective analysis. Am J Clin Oncol. 2016;39(3):266–270. doi:10.1097/COC.0000000000000054.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.